Are Pap Smears Still Necessary?


It’s that time again: time for resolutions, a new start, and scheduling those dreadful annual health exams.

Thanks to the Pap smear, we are not only able to detect cervical cancer, but also premalignant cervical changes responsible for cervical malignancies. Cervical cancer rates have declined by approximately 50% over the past 30 years. With human papillomavirus (HPV) being the most common culprit for the development of cervical cancer, it is important to note how common it is and its effect on cervical cancer rates.

HPV has been widely understood to be the most common sexually transmitted disease, with approximately 90% of cases being not only asymptomatic, but also resolving within two years.

So what’s the link between HPV and cervical cancer?

Persistent infection with high-risk HPV types -- especially types 16 and 18 -- are responsible for approximately 70% of cervical cancer cases worldwide.

Cervical cancer screening used to be quite a simple concept for the lay person: "I go to my Gyn for my annual exam, and I automatically get a Pap smear," But times have changed. The new guideline suggests less frequent screening and the use of a combined Pap smear cytology and HPV screening

This brings us to the new debate: HPV-only testing.

Last year, the FDA announced the approval of an HPV DNA test to be used as a primary method of cervical cancer screening. This new approval has since sparked intense debate in the healthcare community, which ultimately resulted in an expert panel review by the American Society for Colposcopy and Cervical Pathology (ASCCP) and the Society of Gynecologic Oncology (SGO).

The approved HPV test could be considered a primary cervical cancer screening tool in women aged 25 and over.

There are generally two sides to an argument. Dr. Warner Huh of the University of Alabama stated, "Pap smears are probably missing a fair amount of pre-cancer and cancer in women… The HPV test really outperforms Pap smears when it comes to cancer detection as well as precancerous detection."

Dr. Diana Zuckerman of the National Center for Health Research argues that with so many women contracting HPV without progression to cancer, this method could cause women to undergo unnecessary testing. Additionally, while HPV causes most cervical cancer cases, it does not cause all, and Dr. Zuckerman expresses a valid concern about that: “You could definitely miss out on some women who will in fact develop cervical cancer."

What are your thoughts on this debate? Should the HPV test replace the Pap smear or supplement it?

Related Videos
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Ritu Salani, MD, highlights the possible benefit of a novel targeted therapy and autologous tumor vaccine in patients with platinum-resistant ovarian cancer, and in the maintenance setting after treatment for platinum-sensitive disease.
In addition to potentially moving mirvetuximab into earlier lines of treatment for those with platinum-sensitive ovarian cancer, Ritu Salani, MD, also discusses combining the agent with carboplatin to decrease toxicities and improve quality of life.